Benefits (Research Focus) Combined GHRH + GHS-R activation studied for paired pathway stimulation of the somatotropic axis Pulsatile GH release investigated for physiologic-pattern growth hormone release in research models IGF-1 axis signaling explored for downstream hepatic IGF-1 production and somatotropic endpoints Receptor-pathway differentiation examined for paired GHRH receptor and GHS-R1a receptor pharmacology Hormone selectivity researched for ipamorelins reported minimal off-target effects on cortisol, prolactin, and ACTH What Researchers Look At Plasma GH and IGF-1 dynamics following paired peptide administration Pulsatile vs sustained GH release across paired GHRH and GHS-R stimulation Cortisol, prolactin, and ACTH response panels (selectivity markers) DPP-IV resistance and peptide pharmacokinetic profiles across components Comparative pharmacology versus tesamorelin-based blends and single-component administration Quick Specs Form: Lyophilized white powder CJC-1295 (no DAC): 5 mg per vial Ipamorelin: 5 mg per vial Total Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC (per component) Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound 1: CJC-1295 without DAC (Mod GRF 1-29) Synonyms: Mod GRF 1-29
Int J Mol Sci 2024;25:1517
JAMA Oncol 2(8):1056-64, 2016
Melanotan II | 20mg | 3ml Melanotan Strength 20mg Purity 99% HPLC COA On request Melanotan II (MTII) is a synthetic cyclic heptapeptide analogue of melanocytestimulating hormone (MSH), developed for controlled laboratory investigation of the melanocortin signalling system
They have also been shown to have toxic effects on kidney and cardiovascular cells, which are exacerbated by the presence of other environmental contaminants such as heavy metals
Cancer Genet Cytogenet 1999
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
